Aspirin Per Se (i.e., 2-(acetyloxy)benozic Acid) Patents (Class 514/165)
-
Publication number: 20120294943Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: July 27, 2012Publication date: November 22, 2012Applicant: Wellesley Pharmaceuticals, LLCInventor: David A. DILL
-
Publication number: 20120288488Abstract: Compositions and methods for preventing or controlling bacteria, viruses and parasitic growths that cause diarrhea, pneumonia and septicemia in animals comprising a biocidal system comprised of a primary biocide and a pH buffer component; a cationic or ionic surfactant having an HLB of from about 5 to about 30; a thickening agent; and an aqueous based carrier.Type: ApplicationFiled: January 9, 2012Publication date: November 15, 2012Applicant: NOBLE ION, LLCInventors: Burt R. Sookram, John W. Veenstra
-
Publication number: 20120288561Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: July 27, 2012Publication date: November 15, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120282172Abstract: The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders.Type: ApplicationFiled: May 9, 2012Publication date: November 8, 2012Applicants: Centro de Neurociencias e Biologia Celular, Universidade de CoimbraInventors: João Nuno Sereno de Almeida Moreira, Vera Lúcia Dantas Nunes Caldeira de Moura, Sérgio Paulo de Magalhães Simões, Maria da Conceição Monteiro Pedroso de Lima
-
Patent number: 8304404Abstract: An aspirin-theanine cocrystal composition including a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer combined with the quantity of acetylsalicylic acid in a mixture. The theanine enantiomer may be L-theanine, D-theanine, or DL-theanine.Type: GrantFiled: April 5, 2012Date of Patent: November 6, 2012Assignee: Theaprin Pharmaceuticals Inc.Inventors: Harry G. Brittain, Philip V. Felice
-
Publication number: 20120264692Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: October 11, 2011Publication date: October 18, 2012Applicants: Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL), CELERA CORPORATIONInventors: Lance BARE, James J. DEVLIN, Frits R. ROSENDAAL, Pieter H. REITSMA, Irene D. BEZEMER
-
Publication number: 20120253298Abstract: A tissue thickness compensator may generally comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a third layer comprising a third medicament. The tissue thickness compensator may comprise a first layer comprising a first medicament, a second layer comprising a second medicament, and a reservoir comprising a third medicament disposed within the reservoir. The medicaments may be independently selected from a haemostatic agent, an anti-inflammatory agent, an antibiotic agent, anti-microbial agent, an anti-adhesion agent, an anti-coagulant agent, a pharmaceutically active agent, a matrix metalloproteinase inhibitor, and combinations thereof. Articles of manufacture comprising the tissue thickness compensator and methods of making and using the tissue thickness compensator are also described.Type: ApplicationFiled: March 28, 2012Publication date: October 4, 2012Applicant: Ethicon Endo-Surgery, Inc.Inventors: Cortney E. Henderson, Taylor W. Aronhalt, Chunlin Yang, Charles J. Scheib, Venkataramanan Mandakolathur Vasudevan, Mark D. Timmer, Richard W. Timm, Tamara Widenhouse, Steven G. Hall
-
Publication number: 20120244221Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: June 4, 2012Publication date: September 27, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120237574Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: June 4, 2012Publication date: September 20, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120225100Abstract: A personal health care article. More particularly, a personal health care article comprising at least one porous disintegratable solid substrate comprising: from about 1% to about 70%, by weight of said substrate, of a surfactant, from about 10% to about 70%, by weight of said substrate, of one or more polymers, from about 0.025% to about 85%, by weight of said substrate, of one or more health care actives, optionally a plasticizer, and optionally an aesthetic agent wherein said article is ingestible. The invention also comprises a process for making a personal health care article.Type: ApplicationFiled: March 1, 2012Publication date: September 6, 2012Inventors: Trevor John Darcy, Steven Ray Gilbert, Robert Wayne Glenn, JR., Mark Edward Stella
-
Publication number: 20120225812Abstract: The present invention provides substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The present invention also provides process of preparation of compounds of formula (I).Type: ApplicationFiled: November 9, 2010Publication date: September 6, 2012Applicant: Advinus Therapeutics LimitedInventors: Vidya Ramdas, Summon Koul, Sujay Basu, Yogesh Waman, Yogesh Shejul, Dinesh Barawkar, Ventaka Poornapragnacharyulu Palle
-
Publication number: 20120225931Abstract: The present invention relates, inter alia, to methods and compositions for regulating the host response to biomaterials, including inhibiting inflammation from and rejection of biomaterials using salicylate compounds and/or TLR7/TLR9 antagonists as described herein.Type: ApplicationFiled: September 28, 2010Publication date: September 6, 2012Applicant: Yale UniversityInventors: Wajahat Z. Mehal, Themis Kyriakides
-
Publication number: 20120213869Abstract: A pain relieving composition that includes an anesthetic in the range of 0.5%-7.0% by weight (“w/w”), an anti-inflammatory agent in the range of 1.0%-11.0% w/w, a moisturizing agent in the range of 0.5%-12.0% w/w, a humescent in the range of 0.5%-13.0% w/w, a penetration enhancing agent in the range of 0.5%-7.0%, and a carrier solvent in the range of 40.0%-97.0% w/w to be used before and/or after procedures which cause damage to human skin.Type: ApplicationFiled: February 23, 2011Publication date: August 23, 2012Applicant: MISS SMARTY PANTS ENTERPRISES, INC.Inventor: Edna Ma
-
Patent number: 8236857Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: GrantFiled: March 19, 2012Date of Patent: August 7, 2012Assignee: Wellesley Pharmaceuticals, LLCInventor: David A. Dill
-
Patent number: 8236856Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: GrantFiled: March 19, 2012Date of Patent: August 7, 2012Assignee: Wellesley Pharmaceuticals, LLCInventor: David A. Dill
-
Publication number: 20120178724Abstract: In accordance with the present invention, novel methods and formulations are provided for treating and preventing the incidence of drug-induced pro-arrhythmia, including torsades de pointes. The methods and formulations comprise a combination of a drug that induces torsade de pointes, such as Class III antiarrhythmics, certain antimicrobials, antihistamines, antidepressants, antipsychotics, diuretics, with an aspirin and/or a statin. In certain embodiments, the compositions and methods for treatment comprise azimilide and aspirin and/or a statin. These compositions may be administered by different routes, including orally. In certain embodiments where the antiarrhythmic is azimilide it may be administered orally in a dose of about 25 mg to about 300 mg.Type: ApplicationFiled: March 22, 2012Publication date: July 12, 2012Applicant: WARNER CHILCOTT COMPANY, LLCInventors: Joseph Michael Sprafka, II, Jose Mauro Goulart-Brum
-
Patent number: 8211876Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: December 24, 2009Date of Patent: July 3, 2012Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20120164221Abstract: The present invention relates to solid pharmaceutical combinations for oral administration comprising nicotinic acid or a nicotinic acid compound or mixtures thereof in an extended release form and an HMG-CoA reductase inhibitor, which are useful for altering lipid levels in subjects suffering from, for example, hyperlipidemia and atherosclerosis, without causing drug-induced hepatotoxicity, myopathy, or rhabdomyolysis.Type: ApplicationFiled: October 27, 2011Publication date: June 28, 2012Inventors: David J. Bova, Josephine Dunne
-
Publication number: 20120164192Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: March 19, 2012Publication date: June 28, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120164193Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: March 19, 2012Publication date: June 28, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120157416Abstract: The present invention relates to a process for preparing a comestible product comprising xylitol said method comprising: (a) subjecting a composition comprising xylitol in an amount ranging from about 60% to about 100% by weight to extrusion treatment inside an extrusion apparatus under conditions sufficient to form and maintain the xylitol in a slurry and (b) then shaping the extruded slurry and cooling the product to form a solid. The present invention additionally is directed to a product produced therefrom.Type: ApplicationFiled: August 30, 2010Publication date: June 21, 2012Applicant: HERSHEY FOODS CORPORATIONInventors: Steven M. Kumiega, Thomas J. Carroll, Ashley L. Boldt, Paula M. Gibson, Robert J. Huzinec, Burton Douglas Brown, David M. Stumpf
-
Publication number: 20120156261Abstract: There has been a need for an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity and can sustain a sufficient hardness even under humid conditions after opening. Disclosed are a disintegrating particle composition which is prepared by dispersing, in the presence of water, mannitol, xylitol, an inorganic excipient, a disintegrating agent and carmellose and drying, and an orally rapidly disintegrating tablet which comprises said disintegrating particle composition, an active substance and a disintegrating agent. The disintegrating tablet has a good texture and taste, an appropriate hardness and good disintegrating properties and can sustain a sufficient hardness under humid conditions.Type: ApplicationFiled: August 11, 2010Publication date: June 21, 2012Inventors: Keiichi Fujiwara, Tadashi Fukami, Haruka Koizumi
-
Publication number: 20120148636Abstract: A process for producing micronized dispersed micro-particles and to micro-particles produced by this process.Type: ApplicationFiled: June 24, 2010Publication date: June 14, 2012Inventors: Colin Berrido, Peter Rabke, Hans-Jurgen Huppert
-
Publication number: 20120149668Abstract: Provided here in are, inter alia, methods of determining whether a patient is resistant or sensitive to glucocorticoid therapy.Type: ApplicationFiled: February 17, 2009Publication date: June 14, 2012Applicant: SHRINERS HOSPITAL FOR CHILDRENInventors: David G. Greenhalgh, Kiho Cho
-
Publication number: 20120141554Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: January 4, 2012Publication date: June 7, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. Dill
-
Publication number: 20120135050Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent formulated for extended-release.Type: ApplicationFiled: January 4, 2012Publication date: May 31, 2012Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. DILL
-
Publication number: 20120135078Abstract: A xanthine oxidase inhibitor for use in the treatment of angina is described. The angina may be stable angina pectoris and the treatment may be to eliminate, reduce or alleviate one or more symptoms of angina pectoris (such as chest pain), or may be prophylactic. The xanthine oxidase inhibitor may be used in combination with one or more additional therapeutic agents, such as anti-anginal agents. Pharmaceutical compositions, medicaments and kits for the treatment of angina are also described.Type: ApplicationFiled: June 1, 2010Publication date: May 31, 2012Applicant: University of DindeeInventor: Allan Struthers
-
Patent number: 8183232Abstract: An external preparation containing acetylsalicylic acid or its pharmaceutically acceptable salt as an active ingredient for treating anal diseases having therapeutic activity on hemorrhoids (internal hemorrhoid, external hemorrhoid), hemorrhoidal disease owing to anal fissure and other anal diseases together with activity on pain and pruritus.Type: GrantFiled: February 17, 2004Date of Patent: May 22, 2012Assignee: Teikoku Seiyaku Co., Ltd.Inventors: Yukiko Inamoto, Seiichiro Kawabata, Mitsuhiro Kawada
-
Publication number: 20120122823Abstract: Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.Type: ApplicationFiled: September 13, 2011Publication date: May 17, 2012Applicant: Bev-RX. Inc.Inventor: Kyle A. Reed
-
Publication number: 20120122822Abstract: Disclosed are a composition for reducing beta amyloid-induced neurotoxicity by inhibiting ?-secretase activity, comprising a dibenzofuran derivative, and a method for preparing the same. Further disclosed is that the combination of the dibenzofuran derivative with a ?-secretase inhibitor or an anti-inflammatory agent shows higher activity with respect to reducing beta amyloid-induced neurotoxicity.Type: ApplicationFiled: November 17, 2010Publication date: May 17, 2012Applicant: Phloronol, Inc.Inventors: Bong-Ho LEE, Seongho KIM, Hyeon-Cheol SHIN, Haengwoo LEE
-
Patent number: 8173625Abstract: A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic acid. The composition may be created by a method including the steps of: (i) providing a quantity of acetylsalicylic acid; (ii) adding a quantity of a theanine enantiomer to the quantity of acetylsalicylic acid to form a mixture comprising the quantity of acetylsalicylic acid and the enantiomer of theanine; (iii) wetting the mixture; and (iv) grinding the mixture for a length of time sufficient to produce a dried crystalline mass. The water-soluble cocrystal composition is suitable for intravenous administration, preferably to humans.Type: GrantFiled: May 8, 2009Date of Patent: May 8, 2012Assignee: Theaprin Pharmaceuticals Inc.Inventors: Harry G. Brittain, Philip V. Felice
-
Publication number: 20120093759Abstract: Medical devices, wound dressings, and methods of dressing wounds are described. Devices and methods using silicone and pharmaceutically active agents are described. Devices including covers and bases are described.Type: ApplicationFiled: November 17, 2011Publication date: April 19, 2012Inventor: David J. Vachon
-
Publication number: 20120088742Abstract: Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylic acid addition salt (gamma-butyrobetaine acetylsalicylate), L-carnitine acetylsalicylic acid addition salt and 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent.Type: ApplicationFiled: June 21, 2010Publication date: April 12, 2012Applicant: Tetra, SiaInventors: Ivars Kalvins, Anatolijs Birmans, Maris Veveris, Antons Lebedevs, Anatolijs Misnovs
-
Publication number: 20120076834Abstract: Dosage forms provided with protective coatings in which a core comprising at least one acidic active ingredient is provided with at least one inner and one outer coating layer, where the outer layer comprises, as component A, a cationic polymer which is an emulsion polymer of N,N-diethylaminoethyl methacrylate and further monomers.Type: ApplicationFiled: September 27, 2011Publication date: March 29, 2012Applicant: BASF SEInventors: Karl Kolter, Maximilian Angel
-
Publication number: 20120064156Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: ApplicationFiled: August 23, 2011Publication date: March 15, 2012Inventor: John R. Plachetka
-
Patent number: 8129362Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).Type: GrantFiled: July 13, 2007Date of Patent: March 6, 2012Assignee: Galderma Research & DevelopmentInventors: Marie-Line Abou Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
-
Patent number: 8119618Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: March 11, 2009Date of Patent: February 21, 2012Assignee: The Board of Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20120040938Abstract: Provided here in are, inter alia, methods of determining whether a patient is resistant or sensitive to glucocorticoid therapy.Type: ApplicationFiled: March 4, 2009Publication date: February 16, 2012Applicant: SHRINERS HOSPITAL FOR CHILDRENInventors: Kiho Cho, David G. Greenhalgh
-
Patent number: 8114400Abstract: The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.Type: GrantFiled: November 14, 2007Date of Patent: February 14, 2012Assignee: Bayer Pharma AktiengesellschaftInventors: Hartmut Schirok, Joachim Mittendorf, Johannes-Peter Stasch, Frank Wunder
-
Publication number: 20120034302Abstract: A particulate material for delivering an active ingredient and a method for making the same is provided. The particulate material can be included in a solid dosage form to provide both high tablet strength and smooth-dissolving mouth-feel. The particulate material includes at least two low moldability sugars, such as, dextrose and sucrose, in an amount of from about 70% to about 100% of the particulate material and is granulated in the presence of a binding agent.Type: ApplicationFiled: February 5, 2010Publication date: February 9, 2012Inventors: Liangping Yu, Carl Baker, Doug DeSisto, SR., Paul Richardson
-
Publication number: 20120015904Abstract: The present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient ischemic attacks (TIA).Type: ApplicationFiled: July 14, 2011Publication date: January 19, 2012Applicant: Regents of the University of CaliforniaInventors: Frank SHARP, Xinhua ZHAN, Glen C. JICKLING, S. Claiborne JOHNSTON
-
Publication number: 20120009174Abstract: This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention.Type: ApplicationFiled: May 26, 2009Publication date: January 12, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jennifer Van Eyk, Simon Sheng, Qin Fu
-
Publication number: 20120009172Abstract: The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in combination with a second agent which can be aspirin or a thrombolytic agent.Type: ApplicationFiled: September 16, 2011Publication date: January 12, 2012Applicant: Portola Pharmaceuticals, Inc.Inventors: Daniel D. Gretler, Pamela B. Conley, Patrick Andre, Athiwat Hutchaleelaha, David R. Phillips, Anjali Pandey, Robert M. Scarborough, Carroll Anna Crew Scarborough, Wolin Huang
-
Publication number: 20120003316Abstract: This invention relates to a multi-configured, transmucosal pharmaceutical dosage form and, more particularly, to a pharmaceutical dosage form which has a single monolithic/heterogeneous layer or a plurality of such layers. The dosage form is suitable for the delivery of one or more pharmaceutical compositions via the buccal, sublingual, rectal, vaginal or transmucosal delivery route in a human or animal body. It provides for selected delivery profiles resulting from, but not limited to, a porosity-enabled composite matrix of one or more layers/components of the pharmaceutical composition/s. The invention also provides for a method of manufacturing said transmucosal pharmaceutical dosage form in a plurality of configurations.Type: ApplicationFiled: June 3, 2009Publication date: January 5, 2012Inventors: Deshika Reddy, Oluwatoyin Ayotomilola Adeleke, Viness Pillay, Yahya Choonara
-
Publication number: 20120004199Abstract: The invention relates to a wound dressing comprising an electrospun scaffold. The scaffold comprises a biodegradable polymer or co-polymer and a nonsteroidal anti-inflammatory drug.Type: ApplicationFiled: March 10, 2010Publication date: January 5, 2012Inventors: Sheila Mcneil, Anthony Ryan
-
Publication number: 20110312922Abstract: The present invention relates to the discovery of a new protein complex in human biological materials that can be used for diagnostic and other purposes. The invention further relates to products, methods and uses related to said protein complex.Type: ApplicationFiled: October 17, 2008Publication date: December 22, 2011Applicant: ERAC ASInventors: Magne K. Fagerhol, Annette Larsen, Tor Magne Madland, Johan G. Brun
-
Patent number: 8080537Abstract: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by a concomitant application of two pharmaceutical compositions, one containing adapalene and the other containing BPO.Type: GrantFiled: May 28, 2009Date of Patent: December 20, 2011Assignee: Galderma Research & DevelopmentInventors: Marie-line Abou-Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
-
Publication number: 20110305709Abstract: The present invention relates to a pharmaceutical composition comprising an inhibitor of stromal interaction molecule 1 (STIM1) or an inhibitor of STIM1-regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai1 (also designated as CRACM1), and optionally a pharmaceutically active carrier, excipient or diluent. The invention further relates to an inhibitor of stromal interaction molecule 1 (STIM1) or an inhibitor of STIM1-regulated plasma membrane calcium channel activity, in particular an inhibitor of Orai1 (also designated as CRACM1), for treating and/or preventing a disorder related to venous or arterial thrombus formation.Type: ApplicationFiled: March 20, 2009Publication date: December 15, 2011Inventors: Attila Braun, Christoph Kleinschnitz, Bernhard Nieswandt, Guido Stoll, Dávid Varga-Szabó
-
Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives
Publication number: 20110300216Abstract: A tablet comprising: (a) an active ingredient; and (b) at least one member of an effervescent couple, wherein said tablet dissolves in water in not more than three minutes and in the mouth in not more than thirty seconds, and wherein said tablet is capable of acting as an effervescent tablet, a rapid-dissolve tablet or a rapidly disintegrating swallow tablet.Type: ApplicationFiled: June 3, 2010Publication date: December 8, 2011Inventors: Eric R. First, Ashish Bipin Patel, Hung-Huar Tong -
Publication number: 20110301131Abstract: The invention discloses an implant suitable for delivery of at least one drug, the implant comprising a fibrillar collagen matrix having, as measured in Example 1, a viscosity of greater than 100 mPas, optionally greater than 103 mPas, further optionally greater than 106 mPas, still further optionally greater than 109 mPas when a collagen dispersion formed from 140 mg of the fibrillar collagen matrix is dispersed in 25 ml of 2 mM HCl at a pH of less than 3.5 and at a temperature of 30.0+/?0.5° C.Type: ApplicationFiled: November 6, 2009Publication date: December 8, 2011Inventors: Joan Fitzpatrick, David Prior